Shares of Community Health Systems (NYSE:CYH) ended Monday session in red amid volatile trading. The shares closed down -1.20 points or -9.76% at $11.09 with 113.64 million shares getting traded. Post opening the session at $11.91, the shares hit an intraday low of $11.03 and an intraday high of $12.19 and the price vacillated in this range throughout the day. The company has a market cap of $1.46 billion and the numbers of outstanding shares have been calculated to be 113.64 million shares.
Community Health Systems (CYH) on September 19, 2016 announced that the Company, with the assistance of advisors, is exploring a variety of options with financial sponsors, as well as other potential alternatives.
The discussions are at a very preliminary stage and there is no timeline established for this review. There can be no certainty that the exploration will result in any kind of transaction. The Company does not expect to make further public comment regarding these matters while the exploration process takes place.
“Community Health Systems’ primary focus continues to be on delivering high-quality health services in the communities where we operate,” said Wayne T. Smith, chairman and chief executive officer of Community Health Systems, Inc. “Our management team is completely committed to efforts that advance clinical excellence, operational and financial performance and growth strategies that will benefit our organization and the customers we serve.”
Shares of Skyline Medical Inc (NASDAQ:SKLN) ended Monday session in red amid volatile trading. The shares closed down -0.022 points or -10.91% at $0.178 with 81.80 million shares getting traded. Post opening the session at $0.21, the shares hit an intraday low of $0.18 and an intraday high of $0.21 and the price vacillated in this range throughout the day. The company has a market cap of $17.35 million and the numbers of outstanding shares have been calculated to be 81.80 million shares.
Skyline Medical Inc (SKLN) on Sept. 08, 2016 announced the appointment of Paul Sweetnam, Ph.D. to the Company’s Medical Advisory Board (MAB). Dr. Sweetnam brings to Skyline’s MAB more than 25 years of executive and entrepreneurial experience in the pharmaceutical and biotechnology industries. In addition, Dr. Sweetnam has established an extensive network of scientific collaborators within academia, the government and industry.
Skyline Medical’s MAB was formed in July 2013 and provides guidance and advice to the Company to support its product development goals. Including Dr. Sweetnam, the MAB has five members.
“We are delighted that a scientist of Dr. Sweetnam’s stature has agreed to join our MAB,” said Dr. Carl Schwartz, chairman and interim chief executive officer of Skyline Medical. “His impressive credentials include a track record of identifying and integrating disruptive technologies such as high-throughput and profile screening into the drug discovery and development process. We are looking forward to being able to leverage Dr. Sweetnam’s capabilities as we explore the use of the STREAMWAY System filter as a method of sample collection for rapid diagnostics and biomarker identification in the operating room.”